Next Article in Journal
Single Domain Antibody Fragments as Drug Surrogates Targeting Protein–Protein Interactions inside Cells
Previous Article in Journal
Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro
Previous Article in Special Issue
Antibody Drug Conjugates as Cancer Therapeutics
Open AccessReview

Antibody-Directed Phototherapy (ADP)

Faculty of Natural Sciences, Imperial College London, Exhibition Road, London, SW7 2AZ, UK
PhotoBiotics Ltd, Montague House, Chancery Lane, Thrapston, Northamptonshire, NN14 4LN, UK
National Medical Laser Centre, Charles Bell House, 67-73 Riding House Street, London, W1W 7EJ, UK
Author to whom correspondence should be addressed.
Antibodies 2013, 2(2), 270-305;
Received: 25 February 2013 / Revised: 3 April 2013 / Accepted: 4 April 2013 / Published: 25 April 2013
(This article belongs to the Special Issue Antibody-Drug Conjugates)
Photodynamic therapy (PDT) is a clinically-approved but rather under-exploited treatment modality for cancer and pre-cancerous superficial lesions. It utilises a cold laser or LED to activate a photochemical reaction between a light activated drug (photosensitiser-drug) and oxygen to generate cytotoxic oxygen species. These free radical species damage cellular components leading to cell death. Despite its benefits, the complexity, limited potency and side effects of PDT have led to poor general usage. However, the research area is very active with an increasing understanding of PDT-related cell biology, photophysics and significant progress in molecular targeting of disease. Monoclonal antibody therapy is maturing and the next wave of antibody therapies includes antibody-drug conjugates (ADCs), which promise to be more potent and curable. These developments could lift antibody-directed phototherapy (ADP) to success. ADP promises to increase specificity and potency and improve drug pharmacokinetics, thus delivering better PDT drugs whilst retaining its other benefits. Whole antibody conjugates with first generation ADP-drugs displayed problems with aggregation, poor pharmacokinetics and loss of immuno-reactivity. However, these early ADP-drugs still showed improved selectivity and potency. Improved PS-drug chemistry and a variety of conjugation strategies have led to improved ADP-drugs with retained antibody and PS-drug function. More recently, recombinant antibody fragments have been used to deliver ADP-drugs with superior drug loading, more favourable pharmacokinetics, enhanced potency and target cell selectivity. These improvements offer a promise of better quality PDT drugs. View Full-Text
Keywords: photodynamic; therapy; antibody targeted; photosensitiser-drug; phototherapy photodynamic; therapy; antibody targeted; photosensitiser-drug; phototherapy
Show Figures

Figure 1

MDPI and ACS Style

Pye, H.; Stamati, I.; Yahioglu, G.; Butt, M.A.; Deonarain, M. Antibody-Directed Phototherapy (ADP). Antibodies 2013, 2, 270-305.

AMA Style

Pye H, Stamati I, Yahioglu G, Butt MA, Deonarain M. Antibody-Directed Phototherapy (ADP). Antibodies. 2013; 2(2):270-305.

Chicago/Turabian Style

Pye, Hayley; Stamati, Ioanna; Yahioglu, Gokhan; Butt, M. A.; Deonarain, Mahendra. 2013. "Antibody-Directed Phototherapy (ADP)" Antibodies 2, no. 2: 270-305.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop